Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed some of the regulatory and legal hurdles that generic and biosimilar companies have to face on the road to market launch.
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed some of the regulatory and legal hurdles that generic and biosimilar companies have to face on the road to market launch.
Transcript
What regulatory and legal delays are expected to impact drug release dates?
Sure, so we're going to be speaking at AMCP [Academy of Managed Care Pharmacy Annual Meeting] in Chicago on both the traditional and specialty pipeline and what regulatory or legal or FDA issues impact drug launches. The first one that will hit is the drug patents and the drug patent thicket, there could be between 3 or 4 and 200 patents on a given molecule. And getting through all those patents inhibit multisource competition and at-risk launches. So, when generic or biosimilar companies are thinking about bringing these multisource products to market, there's sometimes unknown patent protection and if they launched during that unknown patent protection, it's an at-risk launch. So, we'll talk about that a little bit. Settlement agreements between brand companies and biosimilar and generic companies where they meet and decide, "OK, you guys can launch at this date." That avoids litigation and affects timing of launches. FDA advisory committee meetings, especially from a clinical perspective, impact approvals and launches; complete response letters, or CRLs, [there have been] a lot of those in the last few years. We'll mention that. And with the pandemic itself, inspection site delays have delayed launches of molecules over the last couple of years.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More